Plasma p-tau, in combination with cognitive tests and APOE genotyping, seems to greatly improve the diagnostic prediction of AD and predict future metabolic dysfunction (Lussier et al., 2021; Palmqvist et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.